Roswell Park received more than $21.8 million in recent competitive grants and contracts to launch new investigations or continue major research efforts that have shown promise. This includes funding from the National Cancer Institute (NCI) Cancer Moonshot program as well as multimillion-dollar renewals for high-impact projects based
Read more →
September 28 was the occasion for two special honors for Roswell Park Comprehensive Cancer Center’s Philip McCarthy, MD, who was applauded for his achievements by the City of Buffalo and at the inaugural Fire Ball Sickle Cell Awareness Dinner & Award Ceremony. Dr. McCarthy is presented with
Read more →
Roswell Park Comprehensive Cancer Center immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to a common chemotherapy treatment for liver cancer. They hope that their analysis of immune responses among patients receiving sorafenib can lead to more individualized
Read more →TNBC tumors lack 3 key receptors that existing therapies target Team led by Dr. Gokul Das focused on a different receptor, ER-beta They demonstrate that tamoxifen may be effective against many TNBC tumors. One of the mechanisms that makes so-called triple-negative breast cancer (TNBC) notoriously aggressive and
Read more →The team at Roswell Park Comprehensive Cancer Center has reached record levels, growing to a workforce of more than 3,500. The latest appointments announced by Roswell Park President and CEO Candace S. Johnson, PhD, and her senior leadership team mark a milestone for the 121-year-old cancer center,
Read more →The HER2 protein, which encourages the growth of cancer cells, is present in about 20% of all breast cancers. While HER2-positive breast cancers tend to be very aggressive, today the prognosis is generally very good, thanks to the introduction of HER2 inhibitors such as trastuzumab (brand name
Read more →
